Laura J. Schumacher
Net Worth

Last updated:

What is Laura J. Schumacher net worth?

The estimated net worth of Ms. Laura J. Schumacher is at least $161,828,098 as of 17 Dec 2021. She owns shares worth $44,026,868 as insider, has earned $67,401,230 from insider trading and has received compensation worth at least $50,400,000 in AbbVie Inc..

What is the salary of Laura J. Schumacher?

Ms. Laura J. Schumacher salary is $4,200,000 per year as Vice Chairman of External Affairs, Chief Legal Officer & Corporation Sec. in AbbVie Inc..

How old is Laura J. Schumacher?

Ms. Laura J. Schumacher is 62 years old, born in 1963.

What stocks does Laura J. Schumacher currently own?

As insider, Ms. Laura J. Schumacher owns shares in one company:

Company Title Shares Price per share Total value
AbbVie Inc. (ABBV) Vice Chairman of External Affairs, Chief Legal Officer & Corporation Sec. 213,003 $206.7 $44,026,868

What does AbbVie Inc. do?

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV logo
ABBV
AbbVie Inc.
$206.7

Laura J. Schumacher insider trading

AbbVie Inc.

Ms. Laura J. Schumacher has made 15 insider trades between 2013-2021, according to the Form 4 filled with the SEC.

The largest trade she's ever made was exercising 186,106 units of ABBV stock on 24 Jun 2016. As of 17 Dec 2021 she still owns at least 213,003 units of ABBV stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock, $0.01 par value 103,220 $58.88 $6,077,594
Sale
Common Stock, $0.01 par value 177,556 $130.23 $23,123,295
Sale
Common Stock, $0.01 par value 4,114 $130.61 $537,330
Option
Option (Right To Buy) 78,450 $54.86 $4,303,767
Option
Common Stock, $0.01 par value 78,450 $54.86 $4,303,767
Purchase
Common stock, $0.01 par value 25,000 $70.42 $1,760,525
Sale
Common Stock, $0.01 par value 25,000 $80 $2,000,000
Sale
Common Stock, $0.01 par value 25,000 $90 $2,250,000
Option
Common stock, $0.01 par value 94,140 $51.42 $4,840,679
Sale
Common stock, $0.01 par value 94,140 $93.04 $8,758,597
Option
Option (Right to buy) 94,140 $51.42 $4,840,679
Sale
Common stock, $0.01 par value 25,000 $117.85 $2,946,150
Option
Common stock, $0.01 par value 1,143 $96.86 $110,711
Option
Option (right to buy) 1,143 $96.86 $110,711
Sale
Common stock, $0.01 par value 1,143 $96.86 $110,711
Sale
Common stock, $0.01 par value 144,367 $35.88 $5,179,888
Option
Option (right to buy) 144,367 $35.88 $5,179,888
Option
Common stock, $0.01 par value 144,367 $35.88 $5,179,888
Sale
Common stock, $0.01 par value 79,800 $29.23 $2,332,315
Option
Option (right to buy) 79,800 $29.23 $2,332,315
Option
Common stock, $0.01 par value 79,800 $29.23 $2,332,315
Sale
Common stock, $0.01 par value 40,000 $65.25 $2,610,080
Sale
Common stock, $0.01 par value 50,000 $65 $3,250,000
Option
Option (right to buy) 66,300 $28.86 $1,913,617
Option
Common stock, $0.01 par value 186,106 $27.38 $5,095,024
Sale
Common stock, $0.01 par value 186,106 $60.1 $11,185,157
Sale
Common stock, $0.01 par value 25,000 $56.12 $1,402,925
Sale
Common stock, $0.01 par value 25,000 $60.3 $1,507,500
Sale
Common stock, $0.01 par value 4,143 $50.03 $207,283
Option
Common stock, $0.01 par value 8,928 $43.21 $385,779
Option
Option (right to buy) 8,928 $43.21 $385,779
Option
Option (right to buy) 1,039 $30.21 $31,392
Option
Common stock, $0.01 par value 10,475 $31.21 $326,883
Option
Option (right to buy) 774 $32.57 $25,211
Option
Common stock, $0.01 par value 6,408 $32.57 $208,721
Option
Common stock, $0.01 par value 3,776 $32.52 $122,796
Option
Option (right to buy) 3,611 $32.47 $117,242

AbbVie key executives

AbbVie Inc. executives and other stock owners filed with the SEC: